Federal contract award
75A50119C00054
THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN41 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $65.8M |
| Current contract value | $65.8M |
| Potential contract value / ceiling | $65.8M |
| Start date | Sep 26, 2019 |
| Current end date | Mar 30, 2029 |
| Potential end date | Mar 30, 2029 |
| Latest award activity | Sep 23, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 19 of 19 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 23, 2025 | P00018 | $-428 | EOI::PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025)::EOI NOTICE OF TERMINATION FOR CONVENIENCE |
| Jun 30, 2025 | P00017 | $0 | EOI::PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025)::EOI NOTICE OF TERMINATION FOR CONVENIENCE |
| Sep 19, 2024 | P00016 | $7.8M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO ACCOMPLISH ALL OF THE FOLLOWING OBJECTIVES: 1. MOD CLIN0003 TO FUND COA REQUEST 10.3, TO COVER THE CARE AND HANDLING THAT SOUTHERN RESEARCH PROVIDED THE NON-HUMAN PRIMATE SUBJECTS OF THE PK STUDY, PRI |
| Oct 18, 2023 | P00015 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO 1. EXTEND THE PERIOD OF PERFORMANCE FOR THE BASE PERIOD AT NO COST TO THE GOVERNMENT. AS A RESULT OF THIS MODIFICATION THE PERIOD OF PERFORMANCE IS HEREBY CHANGED FROM SEPTEMBER 25,2019 THROUGH OCT |
| Sep 20, 2023 | P00014 | $16.2M | THE PURPOSES OF THIS MODIFICATION ARE TO 1. ADD FUNDING TO OPTION 2 (CLIN 0003) IN THE AMOUNT OF $230,896.03. 2. EXERCISE OPTION 4 (CLIN 0005) IN THE AMOUNT OF $16,012,452.00. 3. CHANGE THE COR FROM MALEN LINK TO CAROL DIAZ-DIAZ |
| Jun 16, 2023 | P00013 | $928.2K | ADD FUNDING TO OPTION 2 (CLIN 0003) IN THE AMOUNT OF $928,249.32. THIS INCLUDES $269,855.08 TO ACCOUNT FOR G&A AND FEE AS WELL AS $658,394.25 FOR ADDITIONAL MANUFACTURE OF ANTI-ID ABS FOR METHODS DEVELOPMENT. |
| Mar 7, 2023 | P00012 | $1.7M | MODIFICATION 12 ADDS FUNDING IN THE AMOUNT OF $1,707,218.18 TO CLIN 0003 OPTION PERIOD 2 |
| Nov 18, 2022 | P00011 | $0 | MODIFICATION 11 EXTENDS THE POP OF BASE PERIOD TO END ON OCTOBER 20, 2023 AT NO EXTRA COST TO THE GOVERNMENT. |
| Jun 28, 2022 | P00010 | $15.9M | REVISED OPTION 2 IS EXERCISED WITH A NEW FUNDING AMOUNT OF $15,899,969. |
| Jun 3, 2022 | P00009 | $0 | NEW CONTRACTING OFFICER FOR THIS CONTRACT IS JONATHAN GONZALEZ |
| May 23, 2022 | P00008 | $747.6K | THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE |
| Mar 4, 2022 | P00007 | $0 | THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE |
| Feb 24, 2022 | P00006 | $0 | THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE |
| Dec 1, 2021 | P00005 | $0 | EO14042 - THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE |
| May 14, 2021 | P00004 | $0 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT; PROCESS DEVELOPMENT; NON-CLINICAL EFFICACY STUDIES; NON-CLINICAL SAFETY STUDIES; MANUFACTURING ACTIVITIES; CLINICAL ACTIVITIES; AND ALL ASSOC |
| Apr 15, 2021 | P00003 | $0 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT; PROCESS DEVELOPMENT; NON-CLINICAL EFFICACY STUDIES; NON-CLINICAL SAFETY STUDIES; MANUFACTURING ACTIVITIES; CLINICAL ACTIVITIES; AND ALL AS |
| Feb 10, 2021 | P00002 | $13.0M | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT; PROCESS DEVELOPMENT; NON-CLINICAL EFFICACY STUDIES; NON-CLINICAL SAFETY STUDIES; MANUFACTURING ACTIVITIES; CLINICAL ACTIVITIES; AND ALL AS |
| Jan 26, 2021 | P00001 | $0 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT; PROCESS DEVELOPMENT; NON-CLINICAL EFFICACY STUDIES; NON-CLINICAL SAFETY STUDIES; MANUFACTURING ACTIVITIES; CLINICAL ACTIVITIES; AND ALL AS |
| Sep 20, 2019 | 0 | $9.5M | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS |
Estimated positioning window
Mar 30, 2028 – Sep 30, 2028
Recompete signal: . Rule-based research score; positioning dates are estimates.
40/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 40/100. Available recorded signals: 35 points.
- Contract end 2029-03-30 (880 days from calculation)
- +15 points
- 2 historical awards in this buyer and category group
- +10 points
- 19 recorded award transactions
- +10 points
- Latest award action: 2025-09-23
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.